Advertisement

Does Change over Time in Delusional Beliefs as Measured with PDI Predict Change over Time in Belief Flexibility Measured with MADS?

  • Louise PenzenstadlerEmail author
  • Anne Chatton
  • Philippe Huguelet
  • Laurent Lecardeur
  • Javier Bartolomei
  • Perrine Brazo
  • Elodie Murys
  • Florent Poupart
  • Serge Rouvière
  • Mohamed Saoud
  • Jérôme Favrod
  • Yasser Khazaal
Original Paper

Abstract

Delusional beliefs and their behavioral consequences are predominant symptoms in patients with psychosis and play an important role in the treatment. Delusional beliefs are a multidimensional concept which can be divided into three components: distress, preoccupation and conviction of delusions. These can be measured using Peters delusions inventory (PDI-21). We question, whether changes in delusional beliefs over time during treatment measured with the PDI-21 can predict changes in belief flexibility measured with the Maudsley assessment of delusions schedule (MADS). We used a group of patients from a randomized controlled trial for a cognitive intervention for psychosis or psychotic symptoms. Aside standard treatment for psychosis, half of the patients took part in a group treatment “Michael’s game”. Patients were assessed at baseline (T1), at 3 months (T2), and at 9 months (T3). We measured delusional beliefs using PDI-21 and belief flexibility with the MADS. One hundred seventy-two patients were included in the analysis. We measured a main effect of PDI-21scores on belief flexibility measured with MADS. PDI-21 Conviction scores predicted outcomes for all measured MADS items. Increasing PDI Distress and Preoccupation scores were predictors for being more likely to dismiss beliefs and change conviction. Time itself was a predictor for changing conviction and being able to plan a behavioral experiment. Overall the changes in PDI scores predicted outcomes for belief flexibility measured with MADS items. The PDI-21 could be a simple and effective way to measure progress in treatment on delusional beliefs.

Keywords

Psychosis Schizophrenia Delusional beliefs Belief flexibility Cognitive behavior therapy 

Notes

Acknowledgements

We thank the participants and the game leaders, as well as Karen Dieben, Gregoire Monney, Virginie Salamin, Dr. Fethi Bretel, Silke Azoulay, Elodie Pesenti, Raoul Krychowski, Andreia Costa Prata, Dr. Alexei Traian, Dr. Thomas Charpeaud, Prof. Daniele Zullino, Prof. Alberto Parabiaghi, Joanne Corpataux, Milena Kriz, Dr. Giacomini, Claude Hayoz (Fondation HorizonSud), Dr. Georges Klein, Phillippe Laffond, Prof. Eric Bonvin, Prof. Sonia Dollfus, Prof. Thierry D’Amato, Prof. Jean-Michel Llorca, Dr. George Berthon, Dr. Céline Plassereaud, Dr. Véronique Roure, Natacha Boureykoff, Marie-Josée Durak, Dr. Maria Teresa Caldera, Dr. Roberta Bossoletti, and Dario Caffaro. Funding: Swiss National Science Foundation Grant 32003B-121038.

Author Contributions

All authors contributed to the study conception and design of the original study. Louise Penzenstadler and Yasser Khazaal contributed to the conception and design of the secondary analysis. The formal analysis was performed by Anne Chatton. The first draft of the manuscript was written by Louise Penzenstadler, Jérôme Favrod and Yasser Khazaal and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Compliance with Ethical Standards

Disclosure of Potential Conflicts of Interest

This study was funded by Swiss National Science Foundation Grant 32003B-121038. Yasser Khazaal and Jérôme Favrod are the authors of the game. The other co-authors declare that the research was conducted in the absence of any commercial or financial relationships that could be conceived as a potential conflict of interest.

Research Involving Human Participants and/or Animals

All procedures performed in studies involving human participants were in accordance with the ethical standards of the national research committees. The ethical committees of all four countries approved the trial. The protocol was registered (International Standard Randomized Controlled Trial Number Register: ISRCTN37178153) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.”

Informed Consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–23.CrossRefGoogle Scholar
  2. 2.
    Lally J, MacCabe JH. Antipsychotic medication in schizophrenia: a review. Br Med Bull. 2015;114(1):169–79.CrossRefGoogle Scholar
  3. 3.
    Garety PA, Freeman D, Jolley S, Dunn G, Bebbington PE, Fowler DG, et al. Reasoning, emotions, and delusional conviction in psychosis. J Abnorm Psychol. 2005;114(3):373–84.CrossRefGoogle Scholar
  4. 4.
    Ward T, Garety PA. Fast and slow thinking in distressing delusions: a review of the literature and implications for targeted therapy. Schizophr Res. 2019;203:80–7.CrossRefGoogle Scholar
  5. 5.
    Wessely S, Buchanan A, Reed A, Cutting J, Everitt B, Garety P, et al. Acting on delusions. I: prevalence. Br J Psychiatry. 1993;163(01):69–76.CrossRefGoogle Scholar
  6. 6.
    Zhu C, Sun X, So SH. Associations between belief inflexibility and dimensions of delusions: a meta-analytic review of two approaches to assessing belief flexibility. Br J Clin Psychol. 2018;57(1):59–81.CrossRefGoogle Scholar
  7. 7.
    Brabban A, Tai S, Turkington D. Predictors of outcome in brief cognitive behavior therapy for schizophrenia. Schizophr Bull. 2009;35(5):859–64.CrossRefGoogle Scholar
  8. 8.
    Verdoux H, Maurice-Tison S, Gay B, Os JV, Salamon R, Bourgeois ML. A survey of delusional ideation in primary-care patients. Psychol Med. 1998;28(1):127–34.CrossRefGoogle Scholar
  9. 9.
    So SH, Peters ER, Swendsen J, Garety PA, Kapur S. Changes in delusions in the early phase of antipsychotic treatment – an experience sampling study. Psychiatry Res. 2014;215(3):568–73.CrossRefGoogle Scholar
  10. 10.
    Mehl S, Werner D, Lincoln TM. Does cognitive behavior therapy for psychosis (CBTp) show a sustainable effect on delusions? A meta-analysis. Front Psychol [Internet]. 2015[cited 2019 Apr 24];6. Available from: http://journal.frontiersin.org/Article/10.3389/fpsyg.2015.01450/abstract.
  11. 11.
    Lincoln TM, Rief W, Westermann S, Ziegler M, Kesting M-L, Heibach E, et al. Who stays, who benefits? Predicting dropout and change in cognitive behaviour therapy for psychosis. Psychiatry Res. 2014;216(2):198–205.CrossRefGoogle Scholar
  12. 12.
    Khazaal Y, Chatton A, Dieben K, Huguelet P, Boucherie M, Monney G, et al. Reducing delusional conviction through a cognitive-based group training game: a multicentre randomized controlled trial. Front Psych [Internet]. 2015 [cited 2019 Apr 24];6. Available from: http://journal.frontiersin.org/article/10.3389/fpsyt.2015.00066/abstract.
  13. 13.
    Khazaal Y, Favrod J, Azoulay S, Finot SC, Bernabotto M, Raffard S, et al. “Michael’s game,” a card game for the treatment of psychotic symptoms. Patient Educ Couns. 2011;83(2):210–6.CrossRefGoogle Scholar
  14. 14.
    Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64(6):663–7.CrossRefGoogle Scholar
  15. 15.
    Shafer A. Meta-analysis of the brief psychiatric rating scale factor structure. Psychol Assess. 2005;17(3):324–35.CrossRefGoogle Scholar
  16. 16.
    Pichot P, Samuel-Lajeunesse B, Lebreaux AM. A new experimenatl form of BPRS. Ann Med Psychol (Paris). 1973;2(2):254–63.Google Scholar
  17. 17.
    Sullivan Pepe M, Anderson GL. A cautionary note on inference for marginal regression models with longitudinal data and general correlated response data. Commun Stat - Simul Comput. 1994;23(4):939–51.CrossRefGoogle Scholar
  18. 18.
    Peters E, Joseph S, Day S, Garety P. Measuring delusional ideation: the 21-item Peters et al. delusions inventory (PDI). Schizophr Bull. 2004;30(4):1005–22.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Louise Penzenstadler
    • 1
    Email author
  • Anne Chatton
    • 1
    • 2
  • Philippe Huguelet
    • 1
    • 2
  • Laurent Lecardeur
    • 3
  • Javier Bartolomei
    • 1
  • Perrine Brazo
    • 3
    • 4
  • Elodie Murys
    • 5
  • Florent Poupart
    • 6
    • 7
  • Serge Rouvière
    • 8
  • Mohamed Saoud
    • 9
  • Jérôme Favrod
    • 10
  • Yasser Khazaal
    • 11
    • 12
  1. 1.Geneva University HospitalsChêne-BourgSwitzerland
  2. 2.Faculty of MedicineGeneva UniversityGenevaSwitzerland
  3. 3.UNICAEN, Imagerie et Strategies Therapeutiques de la schizophrenie (ISTS)Normandie UniversityCaenFrance
  4. 4.UNICAEN, CHU de Caen Normandie, Service de Psychiatrie d’adultes, Centre EsquirolNormandie UniversityCaenFrance
  5. 5.Unité Mobile de PsychiatrieCentre Hospitalier Princesse GraceMonacoMonaco
  6. 6.Laboratoire Clinique Psychopathologique et InterculturelleUniversité de ToulouseToulouseFrance
  7. 7.Centre Hospitalo-Universitaire de ToulouseToulouseFrance
  8. 8.CRESOP, Centre Hospitalier le VinatierBronFrance
  9. 9.PsyR2, INSERM U1028, CNRS UMR5292, PSYR2 Team, Lyon Neuroscience Research Center, Lyon, France Department of Consultation-Liaison PsychiatryUniversité Claude Bernard Lyon 1LyonFrance
  10. 10.La Source, School of Nursing SciencesHES-SO University of Applied Sciences and Arts of Western SwitzerlandLausanneSwitzerland
  11. 11.Addiction Medicine, Department of PsychiatryLausanne University HospitalsLausanneSwitzerland
  12. 12.Research CenterMontreal University Institute of Mental HealthMontrealCanada

Personalised recommendations